These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 23760241

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Recombinant rabies virus expressing IL-21 enhances immunogenicity through activation of T follicular helper cells and germinal centre B cells.
    Zhang Y, Zhou M, Wang Z, Yang J, Li M, Wang K, Cui M, Chen H, Fu ZF, Zhao L.
    J Gen Virol; 2016 Dec; 97(12):3154-3160. PubMed ID: 27902338
    [Abstract] [Full Text] [Related]

  • 43. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
    Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ.
    PLoS Pathog; 2013 Dec; 9(5):e1003389. PubMed ID: 23737747
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system.
    Hooper DC, Phares TW, Fabis MJ, Roy A.
    PLoS Negl Trop Dis; 2009 Oct 06; 3(10):e535. PubMed ID: 19806203
    [Abstract] [Full Text] [Related]

  • 47. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.
    Koraka P, Bosch BJ, Cox M, Chubet R, Amerongen Gv, Lövgren-Bengtsson K, Martina BE, Roose J, Rottier PJ, Osterhaus AD.
    Vaccine; 2014 Aug 06; 32(36):4644-50. PubMed ID: 24962755
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice.
    Hongtu Q, BoLi L, Jianguo C, Shusheng P, Ming M.
    Vaccine; 2023 Nov 22; 41(48):7129-7137. PubMed ID: 37866995
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Pre- and post-exposure safety and efficacy of attenuated rabies virus vaccines are enhanced by their expression of IFNγ.
    Barkhouse DA, Faber M, Hooper DC.
    Virology; 2015 Jan 01; 474():174-80. PubMed ID: 25463615
    [Abstract] [Full Text] [Related]

  • 60. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates.
    Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP.
    J Infect Dis; 2009 Oct 15; 200(8):1251-60. PubMed ID: 19764884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.